CliffBio
small molecule

PICATO

INGENOL MEBUTATE

Loss of exclusivityJuly 2027latest FDA-listed patent expiry
CompanyLeo →View the full company profile on CliffBio

Drug detail

Brand namePICATO
Active ingredientINGENOL MEBUTATE
Strength0.05%
Dosage formGEL
RouteTOPICAL
ModalitySmall molecule
FDA approvalJanuary 2012
Marketing statusDISCN

Listed patents

PatentExpiresType
8278292July 2027product
8716271December 2026use U-1440
9820959December 2026product
9861603December 2026use U-1440
8735375December 2026use U-1440
8536163December 2026use U-1440
8377919December 2026product
9833428December 2026product
8372827December 2026product
8372828December 2026product
9833429December 2026product

More from Leo

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

PICATO patent cliff — loss of exclusivity July 2027 | CliffBio